Article
Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.
Antimicrobial agents and chemotherapy - 1 Jul 2011
Kwara Awewura, Tashima Karen T, Dumond Julie B, Poethke Pamela, Kurpewski Jaclyn, Kashuba Angela D M, Court Michael H, Greenblatt David J
Abstract excerpt
Efavirenz-based antiretroviral regimen is preferred during rifampin-containing tuberculosis therapy. However, current pharmacokinetic data are insufficient to guide optimized concurrent dosing. This study aimed to better characterize the effects of rifampin on efavirenz pharmacokinetics. Subjects were randomized to receive 600 mg efavirenz/day or 600 mg efavirenz with 600 mg rifampin/day for 8 days, with plasma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.